REGiMMUNE

REGiMMUNE is a clinical-stage biopharmaceutical company dedicated to creating innovative immunotherapies for rare diseases and cancer by leveraging underutilized biological opportunities. We specifically target well-characterized biological pathways, supported by compelling scientific data demonstrating their importance in modulating immune responses against diseases. To target novel pathways, we are building robust and efficient discovery capabilities to create and optimize highly differentiated biologic candidates.